FMP
Terns Pharmaceuticals, Inc.
TERN
NASDAQ
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
4.56 USD
-0.03 (-0.658%)
About
ceo
Ms. Amy L. Burroughs M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.ternspharma.com
exchange
NASDAQ
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a smal...
CIK
0001831363
ISIN
US8808811074
CUSIP
880881107
Address
1065 East Hillsdale Boulevard
Phone
650 525 5535
Country
US
Employee
66
IPO Date
Feb 5, 2021
Summary
CIK
0001831363
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
880881107
ISIN
US8808811074
Country
US
Price
4.56
Beta
-0.65
Volume Avg.
896.51k
Market Cap
294.81M
Shares
-
52-Week
3.26-13.51
DCF
1.11
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.59
P/B
-
Website
https://www.ternspharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TERN News
It looks like there's no news available.
